The diagnostic value of circulating miRNA-125b and miRNA-144 in gestational diabetes mellitus

yanying wu; Lijie Shen; Xin Zhang; Fengzhen Guo

doi:10.18282/po4825

yanying wu Department of Nursing,Xingtai Medical College, Xingtai City, Hebei Province, China,054000
Lijie Shen Department of Radiotherapy and Chemotherapy, Second Affiliated Hospital of Xingtai Medical College, Xingtai City, Hebei Province, China,054000
Xin Zhang Department of Nursing,Xingtai Medical College, Xingtai City, Hebei Province, China,054000
Fengzhen Guo ^* Department of Basic Medicine,Xingtai Medical College, Xingtai City, Hebei Province, China,054000

Article ID: 4825

Abstract

Abstract - Background: Gestational diabetes mellitus (GDM) poses a major threat to maternal and fetal health, and it is essential to find reliable biomarkers for early diagnosis. Circulating micrornas (mirnas) have shown great diagnostic potential in metabolic diseases. This study aims to evaluate the expression pattern and diagnostic value of peripheral blood miRNA-125b and miRNA-144 in GDM patients. Methods: A case-control study was conducted. Peripheral blood samples were collected from 120 pregnant women (60 GDM patients and 60 healthy controls) at 24-28 weeks of gestation. The expression levels of miRNA were quantified by qRT-PCR, and the diagnostic efficacy was analyzed by receiver operating characteristic (ROC) curve. Results: The expression of miRNA-125b in the GDM group was significantly down-regulated (0.45±0.12 vs. 1.00±0.18, p<0.001), while the expression of miRNA-144 was significantly up-regulated (2.83±0.67 vs. 1.00±0.21, p<0.001). The AUC of miRNA-125b in the diagnosis of GDM was 0.87(95%CI: 0.81-0.93), the sensitivity was 82.5%, and the specificity was 85.0%. The AUC of miRNA-144 was 0.91(95%CI: 0.86-0.96), the sensitivity was 88.3%, and the specificity was 83.3%. The combination of mirNA-125b and GDM significantly improved the diagnostic efficiency (AUC: 0.95, sensitivity 93.3%, specificity 90.0%). Conclusions: Circulating miRNA-125b and miRNA-144 are significantly differentially expressed in GDM patients and can be used as efficient non-invasive biomarkers for the diagnosis of GDM. The combination of mirNA-125b and mirNA-144 has significant clinical value.